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Rationale: In the microenvironment of atherosclerotic lesions, vascular smooth muscle cells 2 
(vSMCs) switch to a dedifferentiated state but the underlying molecular mechanisms driving 3 
this switch are not fully understood. Long noncoding RNAs (lncRNAs) are dysregulated 4 
during vascular pathology, but relatively little is known about their involvement in 5 
controlling vSMCs function. CARMN is a lncRNA located immediately upstream of the 6 
microRNAs (miRNAs) miR-143 and miR-145, both involved in vSMCs function. 7 
Objective: We investigated the role of the lncRNA CARMN, independent from miR-143 and 8 
miR-145, as potential a regulator of vSMC phenotypes in vitro and the consequences of its 9 
loss during the development of atherosclerosis in vivo. We hypothe ized that loss of CARMN 10 
is a primary event controlling the functional switch towards pro-atherogenic vSMC 11 
phenotype and accelerates the development of the plaques in vivo. 12 
Method and Results: Expression of CARMN lncRNA was silenced using GapmeRs in human 13 
coronary arterial smooth muscle cells (hCASMCs), revealing that GapmeR-mediated loss of 14 
CARMN negatively affects miR-143 and miR-145 miRNA expression. RNA sequencing of 15 
CARMN-depleted hCASMCs revealed large transcriptomic changes, associated with vSMC 16 
proliferation, migration, inflammation, lipid metabolism and dedifferentiation. The use of 17 
miR-143 and miR-145 mimics revealed that CARMN regulates hCASMC proliferation in a 18 
miRNA-independent manner. In human and mouse, CARMN and associated miRNAs were 19 
downregulated in advanced versus early atherosclerotic lesions. Using a CRISPR-Cas9 knock-20 
out approach, we explored the implications of CARMN depletion during atherosclerosis in 21 
vivo. Consistent with in vitro   results, the knock-out of CARMN impaired the expression of 22 
miR-143 and miR-145 under homeostatic conditions.  Importantly, when atherosclerosis 23 





















    
    















LGALS3-expressing cells content and altered plaque composition, yielding an advanced 1 
phenotype. 2 
Conclusions: We identified the early loss of CARMN lncRNA as critical event which primes 3 
vSMCs towards a pro-atherogenic phenotype in vitro and accelerates the development of 4 
atherosclerosis in vivo. 5 
 6 
Keywords: cholesterol, non-coding RNA, smooth muscle cells, vascular biology, 7 





















    
    















Nonstandard abbreviations and Acronyms 1 
AAV: adeno-associated virus  2 
ABCA1: ATP-binding Cassette Transporter 1 3 
ABCG1: ATP-binding Cassette Subfamily G Member 1 4 
Acta2: Smooth muscle actin 2  5 
ApoE: apolipoprotein E 6 
ASO: antisense oligonucleotides  7 
SMA: -Smooth Muscle Actin 8 
CARMN: cardiac mesoderm enhancer-associated noncoding RNA 9 
CARMN-/-: CARMN knock-out 10 
CARMN+/+: CARMN wild type 11 
CCL: Chemokine C-C Motif Ligand 12 
CD68: Cluster of Differentiation 68 13 
CD45: Protein Tyrosine Phosphatase Receptor Type C 14 
CMBCD: cholesterol-methyl--cyclodextrin 15 
CXCL1: C-X-C Motif Chemokine 1 16 
CNN1: Calponin 1 17 
COL3a1: Collagen type 3 alpha chain 1 18 
CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats 19 
EdU: 5-ethynyl-2’-deoxyuridine  20 
EGFR: Epidermal Growth Factor Receptor  21 
FACS: fluorescence-activated cell sorting 22 
FISH: Fluorescent In-Situ Hybridization 23 





















    
    















KLF4: Kruppell-like factor 4 1 
IL1-beta: Interleukin 1 beta  2 
IL6: Interleukin 6 3 
ISH: In-Situ Hybridization 4 
LCM: laser capture microdissection 5 
LDLR-/-: low density lipoprotein receptor knock-out 6 
Lgals3: Galectin 3 7 
lncRNA: Long Noncoding RNA 8 
Myh11: Myosin Heavy Chain 11 9 
Myocd: Myocardin 10 
MiRNAs: miRNAs 11 
MMP: Metalloproteases 12 
OPT: Optical Projection Tomography 13 
ORO: Oil Red O 14 
Ox-LDL: Oxidised Low-Density Lipoprotein 15 
PCSK9: Proprotein Convertase Subtilisin/Kexin type 9 16 
PDGF: Platelet-Derived Growth Factor 17 
PDFGRa: Platelet-Derived Growth Factor Receptor alpha 18 
qRT-PCR: Quantitative Real-Time Polymerase Chain Reaction 19 
RNA-seq: RNA sequencing 20 
RNU48: Small Nucleolar RNA 48 21 
TAGLN: Taglin 22 
TSS: Transcriptional Start Sites 23 





















    
    




































    
    
















Atherosclerosis is a chronic and inflammatory condition of the arterial branches and a 2 
leading cause of cardiovascular disease and cerebrovascular disease1. Vascular smooth 3 
muscle cells (vSMCs) have a critical and complex role in atherogenesis. In homeostatic 4 
conditions, adult vSMCs are largely quiescent and characterized by a specific gene 5 
expression pattern and functional properties which define their signature2. However, in 6 
response to pathological environmental stress signals that occur during atherogenesis, 7 
vSMCs lose their contractile signature and switch into a pro-atherogenic phenotype as they 8 
start to proliferate, migrate and lose their typical markers (such as Smooth Muscle Actin 9 
Alpha 2) 3–5. In particular, during the formation of stable plaques, vSMC proliferation and 10 
migration toward the intimal layer are associated with the formation of a stabilizing fibrotic 11 
cap6. Whereas, during the latter stages of disease, the recruitment and activation of 12 
inflammatory cells, the decrease in collagen content and increase in metalloprotease 13 
secretion contribute to the breakdown and dynamic remodeling of the fibrotic cap and the 14 
progression towards rupture-prone plaques7. Therefore, it is critical to unravel and fully 15 
understand these complex regulatory networks to be able to target specific molecular 16 
mechanisms during the progression of atherosclerosis. 17 
Recently, several studies have demonstrated that non-coding RNAs, namely long non-coding 18 
RNAs (lncRNAs) and miRNAs (miRNAs), are crucial regulators of many pathophysiological 19 
processes during atherosclerosis 8–10. Namely, miRNAs miR-143 and miR-145 have been 20 
found to be important regulators of vSMC differentiation and disease-associated phenotypic 21 
switching in response to pro-atherogenic stimuli such as cholesterol loading (water-soluble 22 
cholesterol)11 or PDGF-BB treatment 12–16. Their functions have also been highlighted in 23 





















    
    















spontaneous neointimal lesions in the femoral artery14 17,  dysregulated signaling 1 
pathways14, and regulated vSMC migration 17. However, despite numerous studies 2 
uncovering the importance of miR-143 and miR-145 in diverse disease conditions 14–16,18–22, 3 
their function and regulation remains conflicting in the context of atherosclerosis 16,19. 4 
A long noncoding RNA (lncRNA), named CARMN, is juxta-positioned upstream from miR-143 5 
and miR-14523. This lncRNA was originally identified in human cardiomyocytes and named 6 
Cardiac Mesoderm Enhancer-associated Noncoding RNA (CARMN) 24 25. Previous studies 7 
have demonstrated that a crosstalk may exist between the processing of lncRNA host genes, 8 
such as CARMN, and encoded miRNAs 26 and that the biogenesis of these noncoding 9 
molecules might be mutually exclusive27 and produced RNAs with independent functions28. 10 
Although the functions of miR143 and miR145 have been explored, whether CARMN has an 11 
independent function is not completely elucidated in the context of atherosclerosis. Here, 12 
we demonstrated that CARMN has a function independent from miR-143 and mi-R145 in 13 
regulating vSMC proliferation, whil  vSMC migration or dedifferentiation processes are 14 
regulated through the modulation of miRNA expression in hCASMCs. Moreover, we 15 
uncovered a pivotal role of the CARMN/miRNA locus during the pathophysiology of 16 
atherosclerotic disease in vivo and demonstrated that in CARMN knockout mice, the 17 
development of atheroma was accelerated when compared to wild type mice, thereby 18 
inducing advanced and more vulnerable plaques. 19 
 20 
METHODS 21 
Expanded information about materials and methods are available in the Online Data 22 
Supplement. All supporting data and materials are available within the Online Data 23 





















    
    















Seq data are deposited in the Gene Expression Omnibus database (Ref. GSE158972 and Ref. 1 
GSE165445).  2 
 3 
RESULTS 4 
Expression and subcellular localisation of CARMN lncRNA and associated miRNAs in 5 
primary human CASMCs under basal and stimulated conditions 6 
We first sought to understand the expression and regulation of CARMN in hCASMCs 7 
together with miRNAs miR-143 and miR-145. Publicly available data in Ensembl database 98 8 
show several transcript variants belonging to the complex CARMN locus (Figure 1 A). 9 
Initially, we assessed the expression levels of individual isoforms in hCASMCs, using isoform-10 
specific primers when possible (only isoform 4 was amplified in combination with isoform 9) 11 
(Figure 1 A). Expression data indicated that all the isoforms were detectable in hCASMCs 12 
(Figure 1 B).  Following this, we used common primers capturing all isoforms except 205 and 13 
211, to assess the expression levels of CARMN (Figure 1 A). Based on previous studies, the 14 
function of lncRNAs is related to their subcellular localization29,30, therefore, we next 15 
determined the localization of CARMN in hCASMCs. Subcellular fractionation as well as RNA-16 
FISH indicated that CARMN predominantly localized in the nuclear compartment of 17 
hCASMCs (Online Figure I A, B). Of note, during the course of these experiments, there was 18 
a new release of the Ensembl annotation that includes 7 new potential isoforms (Online 19 
Figure II A), yet all remained detectable by our common primer set. However, considering 20 
that lncRNA annotation is not definitively accurate and that lncRNA are expressed in a cell-21 
specific way, we applied a transcript discovery pipeline to publicly available RNA-Seq data of 22 
hCASMCs obtained by ENCODE (https://www.encodeproject.org/), which did not reveal the 23 





















    
    















that the 3’ end of the most abundant CARMN transcripts is upstream of the miR143/miR145 1 
loci (Online Figure II A). Moreover, we carried out 5’ Rapid Amplification of cDNA Ends and 2 
long-reads sequencing (Oxford Nanopore technology). Both techniques revealed the 3 
presence of main transcriptional start site (TSS), already described in the annotation, but 4 
also detected minor additional (TSS) (Online Figure II B, C). Moreover, the long-read 5 
sequencing revealed 4 major exonic structures all covered by the current annotation and 6 
not including miR143/145 (Online Figure II D). In addition, we found reads mapping to the 7 
miR-143/145 stem-loop which suggested the existence of fragments from the processed pri-8 
miRNA with different 5’ end, one of them shared by CARMN transcripts (Online Figure II E). 9 
Altogether, these analyses confirmed the complexity of CARMN locus. 10 
 11 
Platelet-derived growth factor (PDGF-BB) is one of the main pathogenic cytokines released 12 
at the site of injury with a potent mitogen action to vSMCs 31. To gain insight into the 13 
regulation of CARMN in proliferating VSMCs, we treated serum-starved hCASMCs with 14 
PDGF-BB for 48 hours (Figure 1 C) and assessed the levels of CARMN. CARMN was 15 
significantly downregulated following PDGF-BB stimulation (Figure 1 D). Levels of expression 16 
of miR-143 and miR145 were also significantly decreased (Figure 1 D). It is well established 17 
that vSMC migration from the media to the intima is critically involved in the 18 
pathophysiology of vascular disease, although a difficult process to quantify in human 19 
lesions4. We therefore assessed whether CARMN was dynamically regulated under 20 
migratory stimuli. A scratch was made in a monolayer of serum-starved hCASMCs, and the 21 
levels of CARMN and miR-143/145 were assessed at 5, 10 and 24 hours after scratching 22 
(Figure 1 E). However, no statistical difference was observed in the lncRNA or microRNAs 23 





















    
    















expression of the lncRNA CARMN in primary culture of hCASMCs following the treatment 1 
with water-soluble cholesterol-methyl--cyclodextrin (CMBCD), for 72 hours (Figure 1 G). 2 
CMBCD loading substantially decreased the expression levels of CARMN versus control cells, 3 
and similarly the expression of miR-143 and miR-145 (Figure 1 H) as previously described 11. 4 
Moreover, we observed similar pattern of decrease in CARMN expression using another 5 
model of hCASMC dedifferentiation towards foamy cell-like phenotype 32 by loading cells 6 
with oxidised Low-Density Lipoproteins (ox-LDL) (Online Figure III A-C). Thus, the expression 7 
levels of CARMN lncRNA and associated miRNAs are reduced by the exposure to 8 
proliferative stimuli and CMBCD loading of hCASMCs, which is a critical process during the 9 
pathophysiology of atherosclerosis.  10 
 11 
Knockdown of the human CARMN axis drives the phenotypic transition of hCASMCs 12 
towards a pro-atherogenic phenotype. 13 
To assess the functional importance of CARMN, we utilised an LNA-GapmeR antisense 14 
oligonucleotide (ASOs) approach. We designed two different GapmeRs targeting the introns 15 
of CARMN isoforms (named GapCARMN and GapCARMN2) (Figure 1 A). Following 16 
transfection of hCASMCs with GapCARMN and GapCARMN2, we observed a significant 17 
knockdown of CARMN versus a GapmeR Control (GapCTR) using the common primers 18 
(Figure 2 A, Online Figure III D). Importantly, we confirmed the downregulation of CARMN at 19 
the isoform level using isoform-specific primers (Online Figure III E). Notably, the levels of 20 
miR-143 and miR-145 were also significantly downregulated following GapCARMN and 21 
GapCARMN2 transfection in CASMCs (Figure 2 A and Online Figure III D). Furthermore, to 22 
support the results obtained with intronic-targeting GapmeR (GapCARMN/GapCARMN2), 23 





















    
    















(named GapCARMN3 in this manuscript)25 and confirmed similar changes (Online Figure IV 1 
A). 2 
To understand the role of CARMN in hCASMCs in physiological and pathological conditions, 3 
we analyzed the transcriptomic changes associated with the CARMN-axis depletion using 4 
GapCARMN in untreated hCASMCs (basal), as well as following stimulation upon 5 
proliferation, migration or CMBCD loading (Figure 2 B). The expression of CARMN was firstly 6 
assessed in RNA-seq samples to validate appropriate knockdown (Online Figure IV B). 7 
Following RNA sequencing analysis, principal component analysis (PCA) confirmed clustering 8 
of the sample replicates and showed a clear separation of the GapCARMN-treated samples 9 
from the GapCTR-treated hCASMCs in all analyzed conditions (Online Figure IV C). The PCA 10 
also confirmed an effect of the different treatments at the transcriptomic level. In 11 
particular, we noted the clear separation of the CMBCD-treated cells from their relevant 12 
control cells (Basal_C), showing the strong effect of this stimulus on the hCASMC 13 
transcriptome. We also noticed the proliferation-stimulated samples showed an 14 
intermediate phenotype which can be explained by different responses due to the diverse 15 
cell culture densities of the hCASMCs as well as the point of harvesting following GapmeR 16 
transfection. We analyze  the significant changes in gene expression in GapCARMN versus 17 
GapCTR treated cells for each condition (Online Figure IV D) and found that CARMN 18 
depletion affected a large number of genes, on average 910 genes per condition with 411 19 
up-regulated and 499 down-regulated genes.  In total, we found 2315 genes whose 20 
expression was significantly changed by CARMN depletion and analyzed their expression 21 
profiles (Figure 2 C). The heatmap revealed a largely consistent effect of CARMN-axis 22 
depletion, independent of hCASMC treatment. Gene ontology analysis of the CARMN-axis 23 





















    
    















related to vSMC phenotypic transition towards de-differentiated phenotype (Figure 2 D). 1 
More specifically, we noted enrichment of terms linked to a positive effect on cell migration 2 
and proliferation that are key processes during atherogenesis. Moreover, we investigated 3 
whether the depletion of CARMN-axis affects the transcription factor regulating vSMC 4 
homeostasis, Myocardin (Myocd)33. However, Myocd was undetectable in both our RNA-5 
Seq and by qRT-PCR analysis (Online Figure IV E, F). Interestingly, CARMN-dependent genes 6 
were also involved in lipid metabolism and cholesterol homeostasis. CARMN depletion also 7 
upregulated the expression of pro-inflammatory cytokine genes such as interleukins (IL1-8 
beta, IL6) associated with atherosclerosis progression and CXCL1 and as well as CCL2 9 
chemokines responsible of leucocyte migration and recruitment to the developing lesions 10 
(Figure 2 E) 34,35. Furthermore, we noted a significant upregulation of matrix 11 
metalloproteinase 1 (MMP1) and a significant downregulation of collagen and elastase 12 
genes (COL3a1 and ELN), with expression decreasing in the context of extracellular matrix 13 
remodelling and plaque vulnerability (Figure 2 E) 36,37. Genes regulated by CARMN and 14 
involved in positive regulation of proliferation, migration, regulation of inflammatory 15 
response and response to lipid are reported in Online Data set II. Related to the enrichment 16 
of ‘lipid’ terms in the gene ontology analysis, the heatmap of CARMN regulated genes 17 
revealed the clustering of CMBCD treated samples transfected with GapCTR among all 18 
GapCARMN samples, further suggesting that CARMN-dependent genes were also affected 19 
by CMBCD treatment (Figure 2 C). Therefore, we directly compared the genes regulated by 20 
CARMN in basal condition with genes changed upon CMBCD treatment. Importantly, we 21 
found that about 50% of CMBCD-regulated genes were altered in the same direction upon 22 
CARMN depletion (Figure 2 F), suggesting that CARMN depletion alone promotes a water-23 





















    
    















results show the impact of CARMN depletion on hCASMCs transcriptome and in particular 1 
on cholesterol-regulated genes. Collectively, these results suggest CARMN knock-down 2 
might be an important event which primes vSMCs to the phenotypical transition occurring 3 
in plaques formation and progression. 4 
 5 
Knockdown of CARMN-axis lncRNA activates proliferation, migration and induces partial 6 
dedifferentiation of hCASMCs in vitro. 7 
Considering the results obtained from the transcriptomic analysis of CARMN silenced 8 
hCASMCs, we further deciphered the functional consequence of CARMN axis silencing on 9 
hCASMC phenotypes. Interestingly, the depletion of CARMN significantly increased the 10 
proliferation of hCASMCs in quiescent conditions (0.2%FBS) or under PDGF-BB stimulation 11 
(Figure 3 A, B). Next, we assessed the effect of CARMN depletion on hCASMC migration. 12 
Although the response to the migratory stimulus did not show significant difference in the 13 
expression levels of endogenous CARMN and miR-143/145, the downregulation of CARMN 14 
increased the migration rate of hCASMCs versus cells transfected with GapCTR (Figure 3 C, 15 
D). To further validate the involvement of CARMN in hCASMC CMBCD-induced 16 
dedifferentiation process, we analysed mRNA expression changes of the smooth muscle 17 
identity markers, Actin Alpha 2 (Acta2) and Myosin Heavy Chain11 (Myh11), and activated 18 
macrophage-like genes, Cluster of Differentiation 68 (CD68) and Galectin 3 (Lgals3).  We 19 
confirmed that CARMN depletion leads to significant decrease of Acta2 and Myh11 levels, 20 
with concomitant significant increase of CD68 expression in basal conditions (Figure 3 E, F, 21 
G). However, we did not observe significant change in Lgals3 expression in CARMN-depleted 22 
hCASMCs when compared to control group (Figure 3 H). Moreover, we assessed the 23 





















    
    















associated with vSMC dedifferentiation phenotype38. We did not observe significant change 1 
in the expression of this transcription factor in CARMN-depleted proliferative or de-2 
differentiating hCASMCs (Online Figure V A, B), indicating likely KLF4-independent effects. 3 
Instead, we observed a significant increase in KLF4 in scratched hCASMCs with CARMN-4 
depletion (Online Figure C). In order to robustly characterize hCASMCs phenotypic state 5 
following CARMN depletion, we also took into consideration other typical vSMCs marker 6 
genes such as Calponin1 (CNN1) and Taglin (TAGLN)39,40. However, their expression levels 7 
were not significantly changed following CARMN axis knockdown (Online Figure V D, E), 8 
therefore indicating that CARMN downregulation partially affects the vSMCs signature 9 
under unstimulated conditions. In addition, we investigated the expression of lipid-10 
metabolism associated genes, such as ABCA1 and ABCG111, which were found significantly 11 
upregulated following CARMN knockdown versus control (Online Figure V F, G). We did not 12 
observe the same pattern in the case of Srebpf2, SCD and HMGS1 expression (Online Figure 13 
V H, I, J), indicating the modulation of CARMN partially primes the dedifferentiation towards 14 
a pro-inflammatory phenotype foam-cell like phenotype. These phenotypical changes 15 
observed in hCASMCs were confirmed with a second GapmeR, GapCARMN2 (Online Figure 16 
VI A-E).  Collectively, these data suggest that the manipulation of the CARMN locus 17 
modulates the ability of hCASMCs to proliferate and migrate. In addition to this, the results 18 
obtained indicate that CARMN depletion affects the expression of some of the vSMC 19 
identity genes (Acta2 and Myh11) and increases the levels of some of the CMBCD-regulated 20 
genes (CD68, ABCA1, ABCG1) priming vSMC to a partial dedifferentiation process.  21 
 22 





















    
    















As the GapmeR strategy to downregulate CARMN also affects the expression of the miRNAs, 1 
we designed a rescue experiment to assess the contribution of both CARMN and the 2 
miRNAs to the described phenotypes. We have applied a co-transfection approach to 3 
overexpress the levels of miRNAs by treatment with miR-mimic (mimic-143 and mimic-145) 4 
in combination with GapmeR-mediated CARMN knockdown. We first assessed the efficiency 5 
of this strategy confirming a significant upregulation in the expression of both miRNAs by 6 
qRT-PCR (Figure 4 A). Moreover, to assess their functional effect, we checked the expression 7 
of two miRNAs targets, EGFR and PDGFRa 41,12. These were significantly downregulated 8 
following treatment with mimic143 and mimic145 (mimic143/145) versus mimic control 9 
(mimicCTR) (Online Figure VI F, G). In addition, we observed a significant upregulation of 10 
CARMN following treatment with miR143/145 compared to mimic control. While this 11 
increase might suggest a feedback loop in the modulation of CARMN expression induced by 12 
the hosted miRNAs (Figure 4 B), this modulation did not restore CARMN expression to its 13 
basal levels. We then co-transfected hCASMCs in basal conditions with GapmeR targeting 14 
CARMN (GapCARMN) concomitantly with mimic control (mimicCTR) or a combination of 15 
mimic-143 and mimic-145. CARMN knock-down increased hCASMCs proliferation while the 16 
overexpression of miR-143 and miR-145 did not significantly change the observed increase 17 
in cell proliferation. Therefore, CARMN appears to have independent effect on the 18 
modulation of hCASMCs proliferation at basal conditions (Figure 4 C). In contrast, miR-19 
143/145 overexpression restored the levels of vSMC identity genes modulated by CARMN 20 
depletion, Acta2, Myh11 (Figure 4 D, E, F, G). In addition, the overexpression of miR-21 
143/145 restored hCASMCs migration at basal levels thus rescuing the effects observed 22 
following CARMN depletion (Figure 4 H, I). Taken together, these results suggest that 23 





















    
    















migration and dedifferentiation may be driven through CARMN-mediated regulation of the 1 
miRNAs.  2 
 3 
The expression of CARMN lncRNA and associated miRNAs are downregulated in mouse 4 
and human advanced plaques. 5 
To determine the relevance of CARMN in human atherosclerosis, we assessed the 6 
expression of the lncRNA in atherosclerotic plaques isolated from symptomatic patients 7 
undergoing carotid endarterectomy. Previous RNA-seq analysis performed in stable and 8 
unstable regions of human plaques8, were interrogated and revealed a significant decrease 9 
of CARMN levels in the unstable region versus the stable plaques (Figure 5 A). Moreover, in 10 
the same RNA-Seq data, we interrogated the expression levels of previously identified 11 
CARMN-regulated genes. In agreement with the observations in CARMN knock-down 12 
samples, we found a significant upregulation of metalloproteinase (MMP1), significant 13 
downregulation of elastase (ELN) and a significant increase of pro-inflammatory genes (IL1-14 
beta and CCL2) (Figure 5B), in unstable versus stable plaques, confirming our findings 15 
from in vitro studies through to human atherosclerosis. 16 
 To validate these findings, we analysed CARMN expression levels by qRT-PCR in carotid 17 
artery stenosis plaques isolated from different patients and confirmed the downregulation 18 
of the lncRNA in advanced versus early atheroma. Additionally, we showed the 19 
downregulation of miR-143 and miR-145 in the same samples (Figure 5 C). In order to 20 
identify the cellular localization of CARMN within human plaques, In Situ Hybridization (ISH) 21 
was performed in advanced stable plaques isolated from human carotid arteries of 22 
symptomatic patients. CARMN co-localized with -Smooth Muscle Actin (-SMA), typical 23 





















    
    















within the plaques (Figure 5 D). Moreover, some CARMN RNAs co-localises with the CD45 1 
marker42 confirming the expression in immune cells. However, regions of the CD68/CARMN 2 
positive area appear negative for CD45 in parallel sections, suggesting the possibility of a 3 
non-immune origin for these cells (Figure 5D). 4 
 5 
As CARMN and miR-143/145 are evolutionary conserved, we were able to take advantage of 6 
mouse models to evaluate the expression and characterize the function of the CARMN 7 
locus.  The mouse locus harbours two annotated isoforms of CARMN, and their expression 8 
was analysed using a common primer. To further examine the role of the CARMN in the 9 
pathophysiology of disease, we assessed the expression of the lncRNA and the miRNAs at 10 
different stages of murine atherosclerosis. For this purpose, we investigated the levels of 11 
the CARMN locus in two groups of Low-Density Lipoprotein Receptor Knock Out mice (LDLR-12 
/-): i) mice fed with a 0.25% cholesterol diet for 14 weeks to develop advanced plaques, and 13 
ii) mice fed on regular chow for 14 weeks to promote the formation of early fatty streak. We 14 
first confirmed the plaque stage though qualitative histologic analysis classifying them as 15 
fatty streak, the first visible irregular lesion consisting of atherogenic lipoproteins and 16 
macrophages occurring at the lesion site 43, or advanced atheroma characterized by a large 17 
lipid-rich core, infiltrated macrophages and thin collagen-poor fibrotic cap 44 (Figure 5 E). Oil 18 
Red O (ORO) staining was performed to confirm plaques stages (Online Figure VII A). 19 
We then isolated RNA from atherosclerotic lesions from each aortic root using Laser 20 
Capture Microdissection (LCM) and assessed the expression levels of the lncRNA and 21 
miRNAs. The murine CARMN as well as miR-143 and miR-145 were found significantly 22 
downregulated in advanced lesions versus early plaques (Figure 5 F), confirming the 23 





















    
    















  1 
CARMN axis knockout accelerates atherosclerosis in mice. 2 
Considering the decrease of CARMN in advanced human and murine plaques and in vitro 3 
vSMC functional data, we hypothesized that the loss of murine CARMN would modulate the 4 
development of atherosclerosis in vivo. Therefore, we exploited a CRISPR/Cas9-mediated 5 
gene editing approach to constitutively knock-out (-/-) the CARMN locus. The first exon of 6 
the CARMN transcripts and a 4.8kb portion of the gene promoter were deleted, leaving 7 
exons 2/3 and the miRNA stem loops intact (Figure 6 A). Aortas of mice on normal diet were 8 
used to confirm the deletion at the RNA level by RT-qPCR using primers directed at exon 1 9 
versus wild type controls (CARMN+/+) (Figure 6 B). Using isoform specific primers 10 
downstream of the deletion site, we confirmed the knock-down of both transcripts (Online 11 
Figure VII B, C). We also observed in the same samples the downregulation of miR-143 and 12 
miR-145. Moreover, as part of the characterization of knockout mice we examined the 13 
expression of the lncRNA Braveh art, downstream to CARMN transcript, which was 14 
previously found to be dow regulated following loss-of-function of CARMN in mouse 15 
culture of CPCs8. However, qRT-PCR data indicated that Braveheart expression was not 16 
significantly changed in aortic arches isolated from CARMN-/- versus CARMN+/+ samples 17 
(Online Figu e VII, D). To determine the effect of CARMN deficiency in the pathological 18 
context, we induced atherosclerosis in CARMN-/- mice and C57BL/6Ntac littermate controls 19 
using a validated mouse model of atherosclerosis [3] (Figure 6 C). To achieve long-term 20 
hypercholesterolemia, 8-weeks old CARMN+/+ and CARMN-/- mice were injected with 1012 21 
vector genomes/mouse of the recombinant Adeno-associated Virus serotype 8 (AAV8) to 22 
induce overexpression of Proprotein convertase subtilisin/Kexin type 9 (PCSK9) in the liver. 23 





















    
    















weeks to promote hyperlipidaemia and advanced atherosclerosis. Circulating cholesterol 1 
levels were measured at baseline (prior to virus administration), 6 and 10-weeks post 2 
injection and at sacrifice. Consistent with previous studies validating the AAV-PCSK9-3 
induced model in wild-type animals [3][4], we found increased cholesterol levels in CARMN+/+ 4 
and CARMN-/- animals compared to baseline, demonstrating efficacy of the model (Online 5 
Figure VII E). We found no differences in body weight and plasma cholesterol in CARMN-/- 6 
versus CARMN+/+ animals (Online Figure VII F, G). Additionally, we did not observe significant 7 
differences in circulating immune cells and bone marrow progenitors in the two groups of 8 
animals, suggesting little or no effect on immune cell differentiation and proliferation 9 
(Online Figure VIII, IX, X). We next evaluated the severity of atherosclerosis by histological 10 
analysis in cross-sections in two of the main sites wh re atherosclerosis develops in mice, 11 
the brachiocephalic arteries and the aortic roots. To specifically evaluate the structure and 12 
the volume of the lesions in the brachiocephalic arteries, we used Optical Projection 13 
Tomography (OPT) [5]. Quantification of the resulting 3-dimensional images showed 14 
increased plaque volumes in CARMN-/- animals compared to wild type controls (Figure 6 D). 15 
Analysis of Haematoxylin/Eosin stained section confirmed an increase in plaque area in the 16 
brachiocephalic arteries of CARMN-/- versus CARMN+/+ mice (Figure 6 E-F). Furthermore, we 17 
observed a significant increase of the cross-sectional area of the lesions developed in the 18 
aortic roots of CARMN-/- versus control mice (Figure 6 G-H). We next sought to characterize 19 
the composition of the plaques in the brachiocephalic artery and aortic roots. In the 20 
pathological setting, abnormal proliferation of vSMCs 4 3 and resident macrophages 48 49 21 
represent a key features of developing plaques. Cellular proliferation was analysed by EdU 22 
incorporation. A significant increase in EdU incorporation was observed in the plaques of 23 





















    
    















of cells within the plaques. To further analyse the cellular composition of the plaques, cross-1 
sections of the brachiocephalic arteries were stained for markers of vSMCs Acta2, Myh11, 2 
and a marker for activated macrophages and de-differentiated vSMCs, Lgals3. While the 3 
overall amount of smooth muscle actin-expressing vSMCs and cells positive for Myh11 was 4 
similar among the CARMN+/+ and CARMN-/- groups (Figure 7 C-D and Online Figure X C, D), 5 
the content of Lgals3 in the plaque was found to be significantly increased in the lesions of 6 
CARMN-/- versus wild type controls (Figure 7 E-F). Moreover, the process of collagen 7 
deposition/degradation is a determinant factor in evaluating the structure and the stability 8 
of the plaques and can be used as measure of plaque vulnerability 50,51. Therefore, we 9 
investigated the impact of CARMN-/- on the collagen turnover. Picrosirius red staining of the 10 
brachiocephalic arteries showed a significant decrease in collagen in CARMN-/- versus 11 
CARMN+/+ animals, in line with decreased collagen gene expression observed in vitro. (Figure 12 
7 G, H). However, no significant change was observed in the plaque composition of the 13 
aortic roots of CARMN-/- versus wild type controls (Online Figure VII H-K). The absence of 14 
significant differences betwee  the CARMN-/- and CARMN+/+ groups at the aortic root level 15 
could be explained by the vascular-site specific or temporal differences during plaque 16 
formation 52. Overall, these data suggest that the depletion of CARMN induced the 17 
progression of atherosclerotic lesions to a more vulnerable plaque type.  18 
 19 
DISCUSSION 20 
Here, we comprehensively characterized for the first time the expression and the function 21 
of the CARMN lncRNA loci in hCASMC phenotypes in vitro and identified the functional 22 
consequence of the genetic loss of this lncRNA in the pathological setting of atherosclerosis 23 





















    
    















pathological activated state, with concomitant reduction in the expression levels of both 1 
miR-143 and miR-145. Moreover, we functionally dissected the roles of CARMN and the 2 
miR-143/145 cluster and highlighted that in addition to its role as microRNA host gene, our 3 
data suggest that the CARMN lncRNA has miRNA-independent effects on vSMCs function. 4 
Furthermore, we show loss of CARMN in advanced human and mouse atherosclerotic 5 
lesions compared to matched tissue with stable and less advanced disease regions. Finally, 6 
we show that CRISPR/Cas9-mediated genetic targeting of CARMN in mice leads to 7 
development of more advanced lesions in cholesterol-fed mice. 8 
 9 
We used an RNA sequencing approach to understand the functional consequence of the 10 
modulation of CARMN lncRNA expression in vitro in hCASMCs. Our results reveal that the 11 
loss of CARMN lncRNA expression significantly affects the transcriptional vSMC landscape. In 12 
particular, following CARMN knockdown, hCASMCs gained a gene expression signature 13 
associated with a partially differentiated state towards a more plastic phenotype, and 14 
showed a dysregulation of fundamental biological processes such as proliferation and 15 
migration. Transcriptomic analysis of CARMN at basal condition showed a substantial 16 
overlap with CMBCD-loaded signature, particularly in metabolism and homeostasis of lipids. 17 
Accordingly, we postulated that depletion of CARMN predisposes hCASMCs to acquire early 18 
phenotypic/functional properties of foam-cell like cells, thus priming the pro-atherogenic 19 
phenotype likely contributing to the pathophysiology of CVD. However, the 20 
dedifferentiation process following CARMN and miR-143/145 depletion affected only some 21 























    
    















Recent studies have begun to unravel the complex network of interactions between those 1 
miRNAs that are embedded within so-called host genes26, whose biogenesis can be mutually 2 
exclusive 27 or they can be co-expressed and exert independent functions 28. In our study, 3 
we observed the expression of miR-143 and miR-145 was also affected by CARMN 4 
depletion. This effect could simply be due to the pri-miRNA precursor overlapping CARMN 5 
locus. On the other hand, it is also possible the existence of a regulatory circuit in which 6 
CARMN represents an additional level of post-transcriptional regulation and its 7 
downregulation affects the expression level of the miRNAs. We acknowledge that the 8 
presence of multiple promoters identified for the miRNAs16,20 enhances the challenge to 9 
uncover the existing lncRNA-miRNAs regulatory mechanisms. A recent study highlighted the 10 
possibility for lncRNA host genes to regulate hosted miRNAs via super-enhancer regulatory 11 
regions53 and CARMN was previously shown to be associated with a super-enhancer region 12 
and to increase its activity24. However, the demonstration of the cis-regulatory role of 13 
CARMN in vSMCs would require further studies, including chromatin marks and interaction 14 
analysis in this cell type.  In addition, the literature on the regulation and function of these 15 
miRNAs in atherosclerosis is unclear.  16 
 17 
We used a co-transfection strategy to increase the levels of miR-143/145 in CARMN-18 
depleted vSMCs, allowing to dissect the contribution of CARMN from the miRNAs in vitro.  19 
Albeit the off-target limitation of the co-transfection strategy, our findings suggest that 20 
CARMN regulation of vSMC proliferation may possibly occur independently of the 21 
modulation of miR-143/145 expression. However, further dissociation of CARMN and miR-22 
143 and miR-145 effect remains experimentally challenging due to the genetic complexity of 23 





















    
    















CARMN and mir143/145 using, for example, targeted CRISPR activation, inhibition and 1 
editing approaches on the locus in primary vascular cells and mice. Our data expands the 2 
knowledge on the expression of the lncRNA at early and advanced stages of human and 3 
mouse atherosclerotic plaques. In a clinical setting, CARMN was significantly downregulated 4 
in advanced plaques versus stable lesions isolated by endarterectomy from symptomatic 5 
patients. Additionally, CARMN expression was found significantly reduced in murine 6 
advanced atheroma versus fatty streak. Therefore, we suggest that the dow regulation of 7 
CARMN is a key event associated with the progression to more advanced lesions in CVD.  8 
 9 
To determine whether the functional role of the lncRNA is conserved in vivo, and to 10 
understand the functional consequence of the loss of CARMN during the pathophysiology of 11 
atherosclerosis in vivo, we genetically modulated the expression of the lncRNA in mice 12 
exploiting the CRISPR/Cas9 technology. Previous studies have genetically ablated a region of 13 
the pre-miRNAs stem loop to generate miR-143/145-deficent mice 14,15,17,19. We targeted 14 
the promoter region of the locus encompassing the first exon of CARMN transcripts. This 15 
resulted in the first genetic CARMN-/- model.  In our in vivo atherosclerosis study using 16 
CARMN-/- mice, we foun  increased cellular proliferation in the atherosclerotic lesions of 17 
CARMN-/- ve sus CARMN+/+ animals and a more advanced plaque phenotype in the CARMN-/- 18 
mice. This result can be explained by findings from previous studies where vSMCs within 19 
advanced plaque show high proliferative index54,55,56. The evaluation of plaque composition 20 
revealed a largely unchanged content of typical vSMC markers, -SMA and MYH11. 21 
However, considering that expression of vSMC differentiation markers, such as -SMA and 22 
Myh11, are lost by dedifferentiated vSMCs in advanced plaques 7, the interpretation of 23 





















    
    















vSMC-fate mapping have allowed a more reliable identification of vSMC-derived cells which 1 
contribute to intimal and atherosclerotic lesions formation in injured arteries57,58. We 2 
acknowledge the lack of lineage-tracing mouse model represents a limitation to 3 
unambiguously characterize the plaque composition in our in vivo study. The evaluation of 4 
Lgals3, marker for macrophages and dedifferentiated vSMCs revealed a significant increase 5 
in CARMN-/- versus CARMN+/+ animals. Recently, studies have provided evidence that the 6 
rapid turnover and build-up of macrophages in advanced atherosclerotic plaques is mostly 7 
due to their local proliferation 48,59. Importantly, the large pool of foamy and pro-8 
inflammatory cells expressing Lgals3, was defined among the main features of  lesion 9 
progression toward the advanced state 38. Accordingly, our results show that CARMN-/- 10 
increases the content of Lgals3, thus inducing the progression of the plaques toward an 11 
inflammatory and advanced stage. Collectively, these results reveal the functional role of 12 
CARMN axis to the phenotype observed in vivo and to clearly define the contribution of 13 
CARMN and microRNAs separately is an area for future research. 14 
 15 
The decrease in collagen content within the lesions has been associated with progression to 16 
a more advanced plaque phenotype 60. In this context, previous studies have reported that 17 
lower content of collagen may be due to a reduced synthesis by vSMCs and to an enhanced 18 
degradation by metalloproteases and collagenases 50. In our study, the analysis of total 19 
collagen content within the plaques showed a significant decrease in CARMN-/- versus 20 
CARMN+/+ mice, confirming that CARMN-/- induced a more advanced plaque phenotype. 21 
These results are consistent with the transcriptomic analysis of hCASMCs following knock-22 
down of CARMN, where we observed a decrease in collagen and elastase gene expression 23 





















    
    
















Collectively, our study demonstrates that loss of CARMN axis is an early event in 2 
atherosclerosis, both in mice and human. We have shown that downregulation of CARMN is 3 
detrimental for the maintenance of hCASMCs differentiated state and induces itself a 4 
phenotypic transition toward pro-proliferative phenotype, independently from the 5 
modulation of miR-143/145 cluster. In this research, we have characterized the effect of the 6 
dysregulation of miR-143/145 on the expression of vSMC identity genes and their ability to 7 
migrate. Finally, we have characterized the phenotypical consequence of CARMN depletion 8 
during the development of atherosclerosis in vivo and demonstrated that the knock-out of 9 
CARMN locus altered the composition of the plaques to a more advanced plaque type. 10 
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Figure 1. CARMN expression in basal and stimulated human primary CASMCs. 1 
A) Schematic representation of human CARMN splice variants and pre-miRNAs miR-143 and 2 
miR-145 based on ENSEMBL version (GRCh38/hg38), including the position of the forward 3 
(Fw) and reverse (Rev) primers used to amplify all transcripts, grey arrows (except 4, 10 and 4 
11) and the target region for the GapmeRs, GapCARMN, GapCARMN2 and GapCARMN3. The 5 
black arrows next to each transcript name, indicate the direction of transcription. B) 6 
Expression levels of CARMN transcripts in hCASMCs (n=3) via qRT-PCR using isoform-specific 7 
primers (Isoform 1,2,3,4+9,5,6,7,8,9,10,11, and 12) and common primers (amplifying all 8 
isoforms except 4, 10 and 11). C) Diagram of hCASMCs in basal condition (0.2% FBS) and 9 
treated for 48 hours with PDGF-BB.  Histogram plots obtained by FACS showing the 10 
percentage of hCASMCs (n=3) up-tacking EdU following PDGF-BB treatment and in basal 11 
(0.2% FBS) conditions. Student’s t-test was used to assess statistical significance indicated 12 
with p values. D) QRT-PCR to show expression of CARMN, miR-143 and miR-145 in hCASMCs 13 
(n=3) treated with PDGF-BB.  Stud nt’s t-test was used to assess statistical significance 14 
indicated with p values. E) Diagram of the wound healing assay performed in hCASMCs 15 
(n=3), representative micrographs of hCASMCs scratch assay and migrating cells (Scale bar 16 
100μm) and qRT-PCR showing the expression of CARMN and miR-143/145 G) Diagram of 17 
hCASMCs (n=3) in basal condition (0.2% BSA) and treated with cholesterol-methyl-b-18 
cyclodextrin treated for 72 hours and expression levels of dedifferentiation markers (Acta2, 19 
Myh11, CD68 and Lgals3), CARMN and miR-143/145 by RT-qPCR. Student’s t-test was used 20 
to assess statistical significance indicated with p values. H) qRT-PCR data showing the 21 
expression of CARMN and miR-143/145 in basal (0.2% FBS) and following CMBCD-loading 22 






















    
    
















Figure 2. CARMN-regulated genes relevant to vSMC proliferation, migration and water-2 
soluble cholesterol dependent dedifferentiation  3 
A) QRT-PCR results showing the expression of CARMN, miR-143 and miR145 hCASMCs (n=3) 4 
following transfection with GapmeR targeting CARMN (GapCARMN) and GapmeR control 5 
(GapCTR). Mock indicates un-transfected cells. One-way ANOVA with Bonferroni multiple 6 
comparison test was used to assess statistical significance indicated with p values. 7 
B) Schematic representation of the RNA-seq study design. C) Heatmap (as z-score of 8 
log2(FPKM+1)) of differentially regulated genes by CARMN depletion in all conditions. The 9 
purple box highlights the clustering of all CARMN_KD samples while the red box shows the 10 
CMBCD treated replicates (Cont_KD). D) Graph of selected Go Term (Biological Process). The 11 
analysis was performed on the 2315 genes regulated by CARMN depletion in any conditions. 12 
E) Heatmap (as z-score of log2(FPKM+1)) of selected differentially regulated genes by 13 
GapCARMN and GapCTR in the basal condition with the shortest time of GapmeR 14 
transfection (migration). F) Ve n diagram showing the overlap between genes regulated by 15 
CARMN depletion (in B sal-C condition) and genes regulated by CMBCD treatment (in 16 
GapCTR condition) in the same direction.  17 
 18 
Figure 3. The knockdown of CARMN regulated hCASMC proliferation, migration and 19 
dedifferentiation. 20 
A) Representative FACS plots showing the of EdU uptake in hCASMCs transfected with 21 
GapmeR targeting CARMN (GapCARMN) or GapmeR control (GapCTR). The gate (P4) 22 
indicates the EdU positive cells, the samples are named GapmeR negative control (GapCTR) 23 





















    
    















following transfection with GapCARMN, GapCTR and un-transfected cells (Mock) upon 1 
PDGF-BB stimuli and in 0.2% FBS. One-way ANOVA with Bonferroni multiple comparison 2 
test was used to assess statistical significance indicated with p values. C) Representative 3 
pictures of hCASMCs at 0 and 10 hours from the scratch following transfection with 4 
GapCARMN, GapCTR and Mock in 0.2% FBS medium. Pictures were acquired at 10X 5 
magnification. Scale bar 100µm. D) Quantification of the relative migration distances of 6 
hCASMCs (n=3), obtained using ImageJ tool. One-way ANOVA with Bonferroni multiple 7 
comparison test was used to assess statistical significance indicated with p values. 8 
E), F), G), H) Expression levels of dedifferentiation markers Acta2, Myh11, CD68 and Lgals3 9 
in hCASMCs (n=3) stimulated with water-soluble cholesterol-methyl-b-cyclodextrin (CMBCD) 10 
or 0.2% BSA for 72 hours following transfection with GapCARMN, GapCTR or Mock. One-11 
way ANOVA with Bonferroni multiple comparison test was used to assess statistical 12 
significance indicated with p values. 13 
 14 
Figure 4. CARMN depletion regulated hCASMCs phenotypes in miRNAs-dependent and 15 
independent mode. 16 
A), B) QRT-PCR expression data of miR-143, miR-145 and CARMN relative to housekeeper 17 
gene (RNU and UBC respectively) in GapCARMN, control (GapCTR), a combination of 18 
GapCARMN and mimic control (Gap+mimicCTR) and a combination of GapCARMN and 19 
mimic overexpressing miR143 and miR145 (GapCARMN+mimic143/145). Mock refers to un-20 
transfected control cells. One-way ANOVA with Bonferroni multiple comparison test was 21 
used to assess statistical significance indicated with p values. C) Percentage of EdU positive 22 
hCASMCs (n=3) evaluated by FACS analysis and analyzed using FlowJo software. One-way 23 





















    
    















indicated with p values. D), E), F), G) qRT-PCR expression data relative to Acta2, Myh11, 1 
CD68 and Lgals3, respectively relative to housekeeper gene UBC in the above-mentioned 2 
transfection conditions. One-way ANOVA with Bonferroni multiple comparison test was 3 
used to assess statistical significance indicated with p values. H), I) Quantification of the 4 
relative migration distances of hCASMCs (n=3), obtained using ImageJ tool and 5 
representative images of hCASMCs at 0 and 10 hours from the induction of the scratch. 6 
Images acquired at 10X magnification, scale bar 100µm. One-way ANOVA with Bonferroni 7 
multiple comparison test was used to assess statistical significance indicated with p values. 8 
ns= not significant. 9 
 10 
Figure 5. The CARMN locus is downregulated in human and murine atherosclerosis.  11 
A) Expression level of CARMN and B) Expression level of MMP1, ELN, IL1-beta, CCL2 as FPKM 12 
in paired, stable (n=4) and unstable (n=4) human plaque segments retrieved after 13 
endarterectomy from 4 symptomatic patients. P value obtained based on the raw read 14 
counts using DESeq2. C) Expression of CARMN and miR143/145 in human stable and 15 
unstable plaques isolated through endarterectomy (n=4) determined by qRT-PCR. Mann-16 
Whitney was used to assess statistical significance indicated with p values. D) 17 
Representative bright field images of in-situ detection of CARMN co-localizing with α-SMA, 18 
CD68 or CD45 signal in plaques obtained from carotid artery derived from symptomatic 19 
patients at carotid endarterectomy. Pictures were acquired consecutively at 4X, 10X and 20 
40X magnification Scale bar 50μm. E) Representative Haematoxylin & Eosin staining of 21 
aortic roots isolated from LDLR-/- mice. Pictures were acquired with 4x and 10X 22 
magnification. Scale bar 100μm. F) Expression levels of CARMN and miR143/145 in fatty 23 





















    
    















Microdissection. Mann-Whitney was used to assess statistical significance indicated with p 1 
values. 2 
 3 
Figure 6. Genetic ablation of CARMN affects the area, the volume and the composition of 4 
plaques developed in the aortic arches of CARMN-/- versus CARMN+/+ animals. 5 
Schematic representation of CARMN locus located on mouse chromosome 18 and the 6 
CRISPR/Cas9 deletion of the first exon and 4.8 kilobases of the promoter (total 5 kilobases). 7 
The arrows next to each transcript name, indicate the direction of transcription. The grey 8 
arrows and box indicate where common primers to both isoforms were designed. B) 9 
Validation of knockout strategy by qRT-PCR using common primer set performed on the 10 
aortic arches of CARMN+/+ (n=4) and CARMN-/- (n=6) mice. Mann-Whitney was used to 11 
assess statistical significance indicated with p values. C) Schematic workflow used for the 12 
induction of mouse atherosclerosis using AAV8-mediated overexpression of PCSK9 and high 13 
cholesterol diet in CARMN+/+ and CARMN-/- animals. D) Representative tomographic 14 
reconstruction of pictures obtained by Optical Projection Tomography (black picture) and 15 
non-tomographic projection of the mouse aortic arch (white picture). The arrows indicate 16 
the brachiocephalic artery. Quantification of the plaque volumes in CARMN+/+ (n=7) and 17 
CARMN-/- (n=8) animals performed using CTan software. Student’s t-test was used to assess 18 
statistical significance indicated with p values. E) Representative Haematoxylin & Eosin 19 
staining of cross-sections from brachiocephalic artery of CARMN+/+ and CARMN-/- animals. 20 
Pictures acquired at 10X magnification. Scale bar 200μm. F) Quantification of the plaque 21 
areas at the site of maximum lesion of brachiocephalic arteries in CARMN+/+ (n=10) and 22 
CARMN-/- (n=9) mice, performed using Fiji software. Student’s t-test was used to assess 23 





















    
    















sections from aortic roots of wild type and CARMN-/- animals. Pictures acquired at 5X 1 
magnification. Scale bar 200μm. H) Quantification of plaque area of aortic roots of 2 
CARMN+/+ (n=14) and CARMN-/- (n=15) animals, performed using QuPath software. Student’s 3 
t-test was used to assess statistical significance indicated with p values. 4 
 5 
Figure 7. The genetic knock-out of CARMN increased the expression of Lgals3 in plaques 6 
developed in the aortic arch of CARMN-/- animals versus wild type controls. A) 7 
Representative EdU staining of proliferating cells in plaques from CARMN+/+ and CARMN-/- 8 
animals. Pictures were acquired with 10X magnification. Scale bar 80μm.  B) Quantification 9 
of proliferating cells in plaques of CARMN+/+ (n=10) and CARMN-/- (n=9) animals. Values are 10 
expressed as % of positive nuclei over the total cells counted in the plaque. C) and E) 11 
Representative immunostainings and D) and F) quantification of the positive area for αSMA 12 
and Lgals3 staining respectively in the plaques of CARMN+/+ (n=10) and CARMN-/- (n=9) 13 
animals. Pictures acquired at 10X magnification. Scale bar 200μm. G) Representative 14 
picrosirius red staining and H) quantification of collagen content in the plaques of CARMN+/+ 15 
(n=10) and CARMN-/- (n=9) animals. The pictures were acquired by polarized light 16 
microscopy at 10X magnification. Scale bar 200μm. Student’s t-test was used to assess 17 



























    
    

















Novelty and Significance  3 
What is known? 4 
 De-differentiation of vascular smooth muscle cells (vSMCs) occurs in atherosclerotic 5 
lesions. 6 
  Non-coding RNAs, such as long non-coding RNAs (lncRNAs) and microRNAs 7 
(miRNAs), can regulate key aspects of vascular pathology. 8 
 CARMN is a lncRNA located immediately upstream of miRNAs, miR-143 and miR-145, 9 
which are involved in vSMC function. 10 
What new information does this article contribute? 11 
 CARMN/mir143/mir145 axis can prime vSMCs towards pro-proliferative, pro-12 
migratory and de-differentiated phenotypes, in vitro. 13 
 CARMN lncRNA potentially acts independently of the miRNAs to regulate vSMC 14 
proliferation, whereas migration and de-differentiation phenotypes are likely 15 
modulated by mir143/145 independently. 16 
 CARMN knockout mice develop accelerated atherosclerosis and advanced plaques.  17 
 18 
In this research, the conserved and genetically complex long non-coding RNA CARMN, and 19 
its co-located miRNAs, miR-143 and miR-145, were comprehensively characterized in 20 
human and mouse atherosclerosis.  CARMN transcript down-regulation was associated with 21 
advanced plaque phenotype and CARMN knockout in mouse had increased atherosclerosis. 22 
Downregulation of CARMN/miR-143/miR-145 axis can prime vSMCs towards pro-23 





















    
    















provided evidence that the CARMN lncRNA can act independently of the miRNAs to regulate 1 
vSMC proliferation, whereas migration and dedifferentiation phenotypes were associated 2 
with the modulation of miRNAs expression. While both miRNAs are well known in vSMC 3 
biology, our study begins to dissect the complex genetic interplay between lncRNA host 4 
genes and their associated miRNA in health and disease, both in experimental models and 5 
human. Further, we provide evidence for the fundamental, yet complex role of lncRNAs in 6 
vSMC function.   7 
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